Evaluation of the adverse effect of premature discontinuation of pegylated interferon α-2b and ribavirin treatment for chronic hepatitis C virus infection: Results from Kyushu University Liver Disease Study

Journal of Gastroenterology and Hepatology (Australia)

Volumn 27, Issue 7, 2012, Pages 1233-1240

  Ogawa, Eiichi ^a   Furusyo, Norihiro ^a   Kajiwara, Eiji ^h   Takahashi, Kazuhiro ^b   Nomura, Hideyuki ⁱ   Tanabe, Yuichi ^c   Satoh, Takeaki ^j   Maruyama, Toshihiro ^k   Nakamuta, Makoto ^d   Kotoh, Kazuhiro ^e   Azuma, Koichi ^f   Dohmen, Kazufumi ^g   Shimoda, Shinji ^e   Hayashi, Jun ^a  

^a KYUSHU UNIVERSITY HOSPITAL   (Japan)

^b HAMANOMACHI HOSPITAL   (Japan)

^c Fukuoka City Hospital   (Japan)

^d NATIONAL HOSPITAL ORGANIZATION   (Japan)

^e KYUSHU UNIVERSITY   (Japan)

^f Kyushu Central Hospital   (Japan)

^g CHIHAYA HOSPITAL   (Japan)

^h STEEL MEMORIAL YAWATA HOSPITAL   (Japan)

ⁱ Shin Kokura Hospital   (Japan)

^j Kokura Medical Center   (Japan)

^k KITAKYUSHU MUNICIPAL MEDICAL CENTER   (Japan)

more..

Author keywords

Adverse effect; Hepatitis C virus; Pegylated interferon; Ribavirin

Indexed keywords

ALANINE AMINOTRANSFERASE; PEGINTERFERON ALPHA2B; RIBAVIRIN;

ADULT; AGED; ANEMIA; ARTICLE; AUTONOMIC NEUROPATHY; CEREBROVASCULAR DISEASE; DEPRESSION; DRUG WITHDRAWAL; FEMALE; GENOTYPE; GROUPS BY AGE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HYPERTHYROIDISM; HYPOTHYROIDISM; INSULIN DEPENDENT DIABETES MELLITUS; INTERSTITIAL PNEUMONIA; JAPAN; JAPANESE; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MYASTHENIA GRAVIS; NEUTROPENIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; RETINOPATHY; RHEUMATOID ARTHRITIS; SEX DIFFERENCE; SIDE EFFECT; SKIN MANIFESTATION; THROMBOCYTOPENIA; TREATMENT RESPONSE;

EID: 84862654183     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2011.06965.x     Document Type: Article

References (31)

1. Sheff LB. Natural history of chronic hepatitis C. Hepatology 2002; 36: S35-46.
2. Hayashi J, Kishihara Y, Yamaji K etal. Hepatitis C viral quasispecies and liver damage in patients with chronic hepatitis C virus infection. Hepatology 1997; 25: 697-701.
3. Davis GL, Balart LA, Schiff ER etal. Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. Hepatitis Interventional Therapy Group. N. Engl. J. Med. 1989; 321: 1501-6.
4. Hayashi J, Ohmiya M, Kishihara Y etal. A statistical analysis of predictive factors of response to human lymphoblastoid interferon in patients with chronic hepatitis C. Am. J. Gastroenterol. 1994; 89: 2151-6.
5. Ogawa E, Furusyo N, Toyoda K, Takeoka H, Maeda S, Hayashi J. The longitudinal quantitative assessment by transient elastography of chronic hepatitis C patients treated with pegylated interferon alpha-2b and ribavirin. Antiviral Res. 2009; 83: 127-34.
6. Manns MP, McHutchison JG, Gordon SC etal. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-65.
7. Fried MW, Shiffman ML, Reddy KR etal. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N. Engl. J. Med. 2002; 347: 975-82.
8. Akuta N, Suzuki F, Hirakawa M etal. Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin. Hepatology 2010; 52: 421-9.
9. Hayes CN, Kobayashi M, Akuta N etal. HCV substitutions and IL28B polymorphisms on outcome of peg-interferon plus ribavirin combination therapy. Gut 2011; 60: 261-7.
10. Di Bisceglie AM, Ghalib RH, Hamzeh FM, Rustgi VK. Early virologic response after peginterferon alpha-2a plus ribavirin or peginterferon alpha-2b plus ribavirin treatment in patients with chronic hepatitis C. J. Viral Hepat. 2007; 14: 721-9.
11. Ogawa E, Furusyo N, Toyoda K etal. Excellent superiority and specificity of COBAS TaqMan HCV assay in an early viral kinetic change during pegylated interferon alpha-2b plus ribavirin treatment. BMC Gastroenterol. 2010; 16: 38.
12. Furusyo N, Kajiwara E, Takahashi K etal. Association between the treatment length and cumulative dose of pegylated interferon alpha-2b plus ribavirin and their effectiveness as a combination treatment for Japanese chronic hepatitis C patients: project of the Kyushu University Liver Disease Study Group. J. Gastroenterol. Hepatol. 2008; 23: 1094-104.
13. Russo MW, Fried MW. Side effects of therapy for chronic hepatitis C. Gastroenterology 2003; 124: 1711-9.
14. Fried MW. Side effects of therapy of hepatitis C and their management. Hepatology 2002; 36: S237-44.
15. Simmonds P, Mellor J, Sakuldamrongpanich T etal. Evolutionary analysis of variants of hepatitis C virus found in South-East Asia: comparison with classifications based upon sequence similarity. J. Gen. Virol. 1996; 77: 3013-24.
16. Capuron L, Gumnick JF, Musselman DL etal. Neurobehavioral effects of interferon-alpha in cancer patients: phenomenology and paroxetine responsiveness of symptom dimensions. Neuropsychopharmacology 2002; 26: 643-52.
17. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-IV), 4th edn. Arlington, VA: American Psychiatric Association, 1994.
18. Kainuma M, Furusyo N, Kajiwara E etal. Pegylated interferon α-2b plus ribavirin for older patients with chronic hepatitis C. World J. Gastroenterol. 2010; 16: 4400-9.
19. Smith KJ, Norris S, O'Farrelly C, O'Mara SM. Risk factors for the development of depression in patients with hepatitis C taking interferon-α. Neuropsychiatr. Dis. Treat. 2011; 7: 275-92.
20. Smith AK, Simon JS, Gustafson EL etal. Association of a polymorphism in the indoleamine- 2, 3-dioxygenase gene and interferon-α-induced depression in patients with chronic hepatitis C. Mol. Psychiatry 2011; doi: 10.1038/mp.2011.67.
21. Leutscher PD, Lagging M, Buhl MR etal. Evaluation of depression as a risk factor for treatment failure in chronic hepatitis C. Hepatology 2010; 52: 430-5.
22. Lee DH, Jamal H, Regenstein FG, Perrillo RP. Morbidity of chronic hepatitis C as seen in a tertiary care medical center. Dig. Dis. Sci. 1997; 42: 186-91.
23. Kraus MR, Schäfer A, Faller H, Csef H, Scheurlen M. Paroxetine for the treatment of interferon-alpha-induced depression in chronic hepatitis C. Aliment. Pharmacol. Ther. 2002; 16:1091-9.
24. Schaefer M, Schwaiger M, Garkisch AS etal. Prevention of interferon-alpha associated depression in psychiatric risk patients with chronic hepatitis C. J. Hepatol. 2005; 42: 793-8.
25. Dieperink E, Ho SB, Thuras P, Willenbring ML. A prospective study of neuropsychiatric symptoms associated with interferon-alpha-2b and ribavirin therapy for patients with chronic hepatitis C. Psychosomatics 2003; 44: 104-12.
26. Chapman J, Oser M, Hockemeyer J, Weitlauf J, Jones S, Cheung R. Changes in depressive symptoms and impact on treatment course among hepatitis C patients undergoing interferon-α and ribavirin therapy: a prospective evaluation. Am. J. Gastroenterol. 2011; 106: 2123-32.
27. Raison CL, Borisov AS, Broadwell SD etal. Depression during pegylated interferon-alpha plus ribavirin therapy: prevalence and prediction. J. Clin. Psychiatry 2005; 66: 41-8.
28. Furusyo N, Murata M, Ogawa E etal. Ribavirin concentration in the later stages of 48week pegylated interferon-alpha2b plus ribavirin therapy for chronic hepatitis C is useful for predicting virological response. J. Antimicrob. Chemother. 2011; 66: 1127-39.
29. Thompson AJ, Clark PJ, Singh A etal. Genome-wide association study of interferon-related cytopenia in chronic hepatitis C patients. J. Hepatol. 2011; doi: 10.1016/j.jhep.2011.04.021.
30. Soza A, Everhart JE, Ghany MG etal. Neutropenia during combination therapy of interferon alfa and ribavirin for chronic hepatitis C. Hepatology 2002; 36: 1273-9.
31. Zeuzem S, Andreone P, Pol S etal. Telaprevir for retreatment of HCV infection. N. Engl. J. Med. 2011; 364: 2417-28.